Orthofix Medical (OFIX) Looks Attractive After CMS Reversed Its Reimbursement
Rewey Asset Management’s Q2 2026 “RAM Smid Composite” letter said the composite rose 20.06% in Q2 and 31.15% YTD. It highlighted Orthofix Medical Inc. (NASDAQ:OFIX), noting CMS reversed a May 21 reimbursement code change on July 1. OFIX closed at $11.02 on July 22, with a $441.8M market cap.
How this was made
The 30-second read
Why it matters
The reimbursement reversal is presented as a net positive that could reduce reimbursement overhang and potentially support a re-rating, but the article does not disclose new OFIX-specific financial updates beyond referencing the earlier guidance cut.
Market read
CMS reimbursement reversal is the core catalyst cited, but the article is primarily commentary and does not provide a new OFIX print or filing.
What to watch
The article is an investor letter and does not confirm OFIX’s updated guidance, contract wins, or reimbursement utilization; traders should verify any subsequent OFIX filings or earnings updates.
Background
Rewey Asset Management’s Q2 2026 investor letter discusses Orthofix Medical’s prior drawdown after CMS lowered reimbursement for non-invasive bone growth stimulator devices, then claims CMS reversed the code change on July 1.
Ticker impact
Rewey’s Q2 letter says CMS reversed a reimbursement code change on July 1, which they call a net positive for Orthofix (OFIX).
Near-term sentiment could improve, but the piece is investor-letter commentary rather than a fresh, newly disclosed company action.
The only concrete company-specific facts are the prior May 21 CMS reimbursement cut and the July 1 reversal, but the article does not provide new OFIX filings, guidance, or trading catalysts beyond that recap.
Market effects
Could modestly support sentiment for medical device reimbursement-dependent business models if CMS reversals reduce reimbursement risk.
Limited, as the story is US reimbursement policy read-through for a small-cap medtech.
Low, since CMS is US-specific and the article is not about global regulatory actions.
Counterpoint
A CMS reversal may not fully restore OFIX’s financial trajectory if reimbursement changes take time to translate into orders, payer behavior, and realized revenue.
Key entities
- companyOrthofix Medical Inc.
NASDAQ-listed medical technology company discussed as benefiting from a CMS reimbursement code reversal.
- regulatorCMS
US Centers for Medicare and Medicaid Services, cited as reversing a reimbursement code change on July 1, 2026.
- investment_firmRewey Asset Management
Author of the RAM Smid Composite investor letter that frames OFIX as an overdone selloff.
